Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
The Healthcare M&A Wave
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term
Illumina (ILMN): Bullish Structure Builds After Breakout
Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
Skip the Oura Ring IPO. Buy These 10 Stocks Instead.
Is Grail Stock a Bad-News Buy After Its Recent Pullback?
ILMN Stock Jumps 98.7% in a Year: What's Powering the Surge?
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
Here's Why Illumina (ILMN) is a Strong Momentum Stock
Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy?
David P. King elected to Illumina's Board of Directors
Is This the Right Time to Retain ILMN Stock in Your Portfolio?
Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact
Here Are Friday’s Top Wall Street Analyst Research Calls: Arista Networks, BWX Technologies, Cisco Systems, Danaher, Doximity, Estee Lauder, Illumina, Texas Roadhouse, Workday, and More
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Here's Why Illumina (ILMN) is a Strong Growth Stock
ILMN Stock Up on Q1 Earnings & Revenue Beat, Margins Expand, '26 View Up
Illumina, Inc. (ILMN) Q1 2026 Earnings Call Transcript
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates
Illumina Reports Financial Results for First Quarter of Fiscal Year 2026
Tempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now?
Unlocking Q1 Potential of Illumina (ILMN): Exploring Wall Street Estimates for Key Metrics
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Caprock Group LLC Purchases 5,764 Shares of Illumina, Inc. $ILMN
Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Fortis Capital Advisors LLC Invests $1.26 Million in Illumina, Inc. $ILMN
DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows
Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Hold” by Brokerages
Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
Douglas Lane & Associates LLC Purchases 26,014 Shares of Illumina, Inc. $ILMN
Illumina: Competitive Threats Priced In
Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026
REGN or ILMN: Which Is the Better Value Stock Right Now?
11,218 Shares in Illumina, Inc. $ILMN Acquired by Azzad Asset Management Inc. ADV
Illumina (ILMN) is a Top-Ranked Momentum Stock: Should You Buy?
Illumina, Inc. $ILMN Shares Sold by Aberdeen Group plc
The Personalized Biotech Flywheel Cathie Wood Built Is Still a Winning Bet Today
Illumina Announces Changes to Board of Directors
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Assenagon Asset Management S.A. Trims Holdings in Illumina, Inc. $ILMN
SG Americas Securities LLC Raises Holdings in Illumina, Inc. $ILMN